Background-The mode of death has been well characterized in patients with heart failure and a reduced ejection fraction; however, less is known about the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF). The purpose of this study was to examine the mode of death in patients with HFPEF enrolled in the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial and to determine whether irbesartan altered the distribution of mode of death in HFPEF. Methods and Results-All deaths were reviewed by a clinical end-point committee, and the mode of death was assigned by consensus of the members. The annual mortality rate was 5.2% in the I-Preserve trial. There were no significant differences in mortality rate between the placebo and irbesartan groups. The mode of death was cardiovascular in 60% (including 26% sudden, 14% heart failure, 5% myocardial infarction, and 9% stroke), noncardiovascular in 30%, and unknown in 10%. There were no differences in the distribution of mode-specific mortality rates between placebo and irbesartan. Conclusions-Sixty percent of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure death being the most common. Treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238.
A pproximately half of all patients with chronic heart failure have a normal or near-normal (ie, a "preserved") left ventricular ejection fraction. [1] [2] [3] [4] [5] [6] [7] The demographic characteristics present in patients with heart failure and a preserved ejection fraction (HFPEF) differ significantly from those in patients with heart failure and a reduced ejection fraction (HFREF). Patients with HFPEF are older, are more often female, more often have hypertensive heart disease, and less often have ischemic heart disease than patients with HFREF. [1] [2] [3] [4] [5] [6] [7] Whether overall mortality rates differ between patients with HFPEF and HFREF is not clear. Some community-based epidemiological studies have shown that the annual mortality rate approaches 15% for both groups of patients; others have shown that the mortality rate was significantly lower in patients with HFPEF than HFREF. 1, 4, 5, 7 Data from randomized clinical trials (RCTs) also suggest that patients with HFPEF have a lower annual mortality (approaching 5%) than patients with HFREF. 8 -12 The reasons for these differences between mortality rates in patients with HFPEF and HFREF have not been defined. One postulated explanation is that differences in the underlying pathophysiology alter the distribution of the cause of death, making 1 group more or less vulnerable to specific causes. The mode of death has been well characterized in patients with HFREF ; however, less is known about the mode of death in patients with HFPEF. Defining the cause of mortality in patients with HFPEF will help to improve our understanding of the underlying pathophysiology in these patients with heart failure. In particular, it is important to determine whether these patients die primarily of cardiovascular or noncardiovascular causes.
Clinical Perspective on p 1405
The Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) Trial is the largest RCT to examine patients with HFPEF and has the largest number of mortal events. 12 Eight hundred eighty-one patients randomized to I-Preserve died during the trial. The purposes of this study were to examine the mode of death in patients with HFPEF enrolled in the I-Preserve trial, to determine the frequency with which patients with HFPEF die of cardiovascular events, to examine whether the distribution of the specific mode of death in HFPEF differs significantly from that in patients with HFREF, and to determine whether irbesartan altered the distribution of mode of death in HFPEF.
Methods

Study Design
The study design and primary results of the I-Preserve study have been previously published. 12, 40, 41 Briefly, 4128 patients at least 60 years of age with New York Heart Association (NYHA) class II, III, or IV heart failure and an ejection fraction Ն45% were randomly assigned to receive irbesartan 300 mg/d or placebo. The primary composite outcome was death resulting from any cause or hospitalization for cardiovascular cause (heart failure, myocardial infarction, unstable angina, arrhythmia, or stroke). Secondary outcomes included death or hospitalization for heart failure, death resulting from all causes and cardiovascular causes, and quality of life. During a mean follow-up of 49.5 months, the primary outcome occurred in 742 patients in the irbesartan group and 763 in the placebo group. Primary event rates in the irbesartan and placebo groups were 100.4 and 105.4 per 1000 patient-years, respectively (hazard ratio, 0.95; 95% confidence interval, 0.86 to 1.05; Pϭ0. 35 ). Irbesartan did not improve the outcomes of patients with HFPEF.
The trial was approved by the ethics committee at each participating center, and patients provided written informed consent. The Executive Committee designed and oversaw the trial in collaboration with representatives of the study sponsors (Bristol-Myers Squibb and Sanofi-Aventis), with assistance from a Steering Committee of country leaders. The sponsors and/or a contract research organization collected the trial data, which were then analyzed at the Statistical Data Analysis Center at the University of Wisconsin, Madison, independently of the sponsors, guided by a predefined statistical analysis plan. All investigators and committee members involved in the conduct of the study (except for a Data and Safety and Monitoring Board) were unaware of study group assignment. This manuscript was prepared and submitted for publication by the Executive and Clinical End Point committees, which had unrestricted access to the study data and vouch for the accuracy and completeness of the reported analyses.
Death Adjudication Process
All deaths were reviewed by the Clinical End Point Committee, and the mode of death was assigned by consensus of the members. For each death, the following information was reviewed: case report forms, summary provided by the investigator, hospital death note, discharge summary from previous hospitalizations, autopsy report, and death certificate. Definitions for each mode of death category were prospectively developed by the Clinical End Point Committee and approved by the Executive Committee of the I-Preserve trial before the start of the trial.
Sudden death was defined as an unexpected death in a previously clinically stable patient. Patients in this category had recent human contact before the event. This category includes patients who after attempted resuscitation became comatose and then died. Patients who died and had been out of contact for prolonged (generally Ͼ1 week) or unknown periods of time were classified as unknown. When sufficient information was available, sudden death was subcategorized as with or without preceding cardiovascular symptoms. In the absence of such information, the sudden death event was subcategorized as unknown.
Heart failure death was defined as a death that occurred as a result of worsening or intractable heart failure. The death generally occurred during hospitalization but could have occurred at a nursing home facility or at home during hospice care. Terminal arrhythmias associated with heart failure deaths were classified as a heart failure death. Heart failure secondary to a recent myocardial infarction (MI) was classified as an MI death. Patients with worsening heart failure had many of the following features: symptoms of heart failure, signs on physical examination of heart failure, and diagnostic evidence of heart failure such as an abnormal chest x-ray, significant increase in brain natriuretic peptide (BNP) or N-terminal prohormone BNP (NT-proBNP), or prerenal azotemia.
When sufficient information was available, heart failure death was subcategorized as with or without low output and/or congestion. In the absence of such information, the heart failure death event was subcategorized as unknown. Low output was indicated by fatigue, signs of vasoconstriction, prerenal azotemia, need for vasopressors, low cardiac output, or hypotension. Congestion was indicated by symptoms and signs on physical examination, chest x-ray, and noninvasive and invasive measurements.
MI death was defined as a death that occurred after a verified definite acute MI. In cases of death occurring outside the hospital, a death was classified as an MI death if the autopsy findings showed a recent MI or a recent coronary thrombus. The criteria necessary to satisfy the diagnosis for an acute, evolving, or recent acute MI included two of the following: typical changes in biochemical markers of myocardial necrosis (troponin, total creatine phosphokinase, or creatine kinase-MB), ischemic cardiac symptoms, and ECG change typical of ST-segment elevation or non-ST-segment elevation MI. We chose the following as biochemical indicators for detecting myocardial infarction: maximal concentration of troponin T or I Ն2 times the upper limit of normal on at least 1 occasion, maximal value of creatine kinase-MB Ͼ2 times the upper limit of normal on at least 1 occasion, or total creatine kinase, in the absence of available troponin or creatine kinase-MB assay, Ͼ5 times the upper limit of normal.
The following are ECG indicators for detecting myocardial infarction: ST-segment elevation consisting of new or presumed new ST-segment elevation at the J point in Ն2 contiguous leads with the cutoff points Ն0.2 mV in leads V 1 , V 2 , or V 3 or Ն0.1 mV in other leads; development of a Q wave in lead V 1 through V 3 or the development of a Q wave Ն30 ms (0.03 seconds) in leads I, II, avL, avF, V 4 , V 5 , or V 6 (Q-wave changes must be present in any 2 contiguous leads and Ն1 mm in depth.); or characteristic ST-T-wave changes compatible with non-ST-segment elevation MI. Evidence that would raise the index of suspicion in the absence of clear data on ECG and/or enzyme changes included the use of thrombolytics; angiographic evidence of acute thrombus; echocardiographic, radionuclide, or contrast ventriculography evidence of a new wall motion abnormality; or evidence of infarct complication such as myocardial rupture or papillary muscle dysfunction.
It should be noted that the I-Preserve End Point Committee Charter was written in 2001 to 2002 and used the existing guideline definition of acute MI. To be consistent throughout the length of the trial, this definition was not changed after the publication of the most recent guideline document, "Universal Definition of Myocardial Infarction." 42 Cerebrovascular accident death was defined as a death that occurred after a hospital-verified definite stroke. In cases of death occurring outside the hospital, a death was classified as a cerebrovascular accident death if autopsy findings showed a recent stroke. Stroke was defined as a persistent (Ն24 hours) disturbance of focal neurological function resulting in symptoms thought to be due to atherothrombotic or thrombotic cerebral infarction, embolus, or evidence of hemorrhage or for which there was no certain cause. Diagnosis required characteristic history, physical examination, imaging techniques, and/or autopsy data.
Cardiovascular procedure death was defined as a death that occurred during the operative or perioperative period that could be directly attributed to the procedure itself.
Other cardiac death was defined as a death that could be attributed to a cardiac reason but was not one of the other modes listed above. For example, deaths resulting from valvular heart disease were considered other cardiac deaths.
Other vascular death was defined as a death that could be attributed to a vascular reason. These included such events as pulmonary embolism, aortic dissection, or aortic rupture.
Noncardiovascular death was defined as a death that could be attributed to a noncardiac reason. These included subcategories such as renal, respiratory, cancer, trauma, infection/sepsis, suicide, and other.
Unknown death was defined as a death in which no specific morbid event classification could be assigned. In the present study, this category was analyzed separately.
Statistical Analysis
Differences in demographic characteristics for patients who died and those who did not die, patients with noncardiovascular and those with cardiovascular mortality, and patients with sudden and those with heart failure mortality were examined through the use of 2-sided Student t tests, Wilcoxon rank-sum tests, or Fisher exact tests determined by variable type and distributional shape. Cox proportional-hazards analysis was used to compare the rates of death for each mode of mortality individually and by treatment arm, baseline age, gender, NYHA class, previous hospitalization for heart failure before randomization, NT-proBNP, the presence of diabetes, region, and ejection fraction. To correct for the large number of comparisons made, statistically significant difference was defined as PϽ0.001. This conservative approach was equivalent to a Bonferroni correction for 50 comparisons. If a global Cox proportional-hazards analysis over the multiple levels of NYHA class, ejection fraction, and region was significant at PϽ0.001, then subsequent adjustments to the P values for pairwise comparisons were based on a Bonferroni adjustment for that specific number of comparisons. All P values reported were unadjusted unless otherwise specified.
Results
Demographics
Of the 4128 patients enrolled in I-Preserve, a total of 881 randomized patients died, 436 in the placebo group, 445 in the irbesartan group. There were no statistically significant differences in baseline characteristics between patients who died in the placebo versus the irbesartan group. Some of the baseline characteristics of the patients who died were significantly different from those of patients who did not die ( Table  1) . The patients who died were older; more often were male; more often had atrial arrhythmias, anemia, diabetes, lower GFR, and ischemic heart disease; had more frequent heart failure hospitalizations before randomization; and had a higher baseline NT-proBNP value (all PϽ0.001).
In addition, the demographic data were examined in patients with cardiovascular versus those with a noncardiovascular mortality and in patients with sudden death versus those with heart failure mortality ( Table 2) . Patients with cardiovascular mortality were more likely to have evidence of coronary heart disease. Patients with sudden death were more likely to be taking a loop diuretic and to have decreased renal function.
All-Cause Mortality Rate
The cumulative incidence of all-cause mortality for the patients randomized in the I-Preserve trial was Ϸ25% over 5 years, 5.2% annually, and 52.4/1000 patient-years ( Figure 1 and Tables 3 and 4 ). There were no statistically significant differences in all-cause mortality between the placebo and irbesartan groups ( Figure 1 ).
Mode of Death
Sixty percent of the deaths were cardiovascular, 30% were noncardiovascular, and 10% were unknown. The specific distributions of mode of death categories are shown in Table  3 . There were no statistically significant association between the distribution of mode of death categories between patients in the placebo versus the irbesartan group (Pϭ0.125). Kaplan-Meier cumulative event curves for cardiovascular death, noncardiovascular death, sudden death, and heart failure death are shown in Figures 2 and 3, and event rates for all modes of death are presented in Table 4 . These cumulative event curves demonstrate that the mortalities in each mode of death category occurred in a linear and steady pattern that was equally distributed across the follow-up period and that treatment had no effect on the rate of any mode of death category.
Demographic Factors Associated With Mode of Death
Potential demographic factors that may have affected the event rate of mode of death categories were examined: age, gender, NYHA classification, previous hospitalization before randomization, NT-proBNP, presence of diabetes mellitus, left ventricular ejection fraction, and region of residence. These factors were chosen on the basis of the differences in demographics between patients who died and those who did not die. Results are shown in Table 5 . All demographic variables examined except region had a significant association with rate of all-cause mortality at an ␣ϭ0.001 level, although a less conservative adjustment would consider region to have a significant association (Pϭ0.0075). A significant increase in event rate was seen in all examined modes of death for those Ն75 years of age, NT-proBNP Ͼ339 pg/mL, and presence of diabetes mellitus. Women had a significant decrease in rates of events for all modes except heart failure death. Those who had a previous hospitalization for heart failure had increased rates of events for all modes except noncardiovascular death. NYHA class IV was associated with increased rates of all-cause mortality and cardiovascular death. However, no difference appeared between classes II and III. The lowest left ventricular ejection fraction quartile (Ͻ53%) had significantly higher rates of all-cause mortality, cardiovascular death, and particularly sudden death compared with the other 3 quartiles, which were all compa-rable. The only significant association for region and mode of death was for noncardiovascular deaths; Eastern Europeans saw a much lower rate of noncardiovascular events compared with Western Europeans and North Americans.
Discussion
The purpose of this study was to examine the mode of death in patients with HFPEF enrolled in the I-Preserve trial, to determine the frequency with which patients with HFPEF die of cardiovascular events, to determine whether irbesartan altered the distribution of mode of death in HFPEF, and to examine whether the distribution of the specific mode of death in HFPEF differs significantly from that in patients with HFREF. The results from the present study support the following conclusions. First, 60% of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure being the most common. Second, treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates. Third, the distribution of the PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass graft surgery; BSA, body surface area; and ACE, angiotensin-converting enzyme.
*Cause of heart failure was designated by the investigator. mode of death categories in patients with HFPEF appeared to be different than that reported for patients with HFREF, with HFPEF patients having more noncardiovascular, fewer sudden, and fewer heart failure deaths than HFREF patients.
Comparison With Other HFPEF RCTs
In addition to I-Preserve, 3 other RCTs examined patients with HFPEF and reported some data on the distribution of the mode of death categories (Table 5) . 8 -12 I-Preserve provided the largest sample size of mortal events; in fact, the number of deaths in I-preserve exceeded all of the deaths in the other 3 studies combined. The percent of noncardiovascular deaths was nearly identical in all 4 studies. In addition, the incidence of sudden death was similar between I-Preserve and Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM-Preserved). However, the rate of heart failure death was lower in I-Preserve than in CHARMPreserved or the Digitalis Investigator Group (DIGPreserved) study. This difference in heart failure death may relate in part to the differences in ejection fraction, sex, and ischemic heart disease in CHARM-Preserved versus I-Preserve. For example, in CHARM-Preserved, 35% of the patients had an ejection fraction Ͻ50% compared with 12% in I-Preserve. I-Preserve had fewer patients with ischemic heart disease and more women than CHARM-Preserved. As the analyses in the present study demonstrated, an ejection fraction Ͻ50%, the presence of ischemic heart disease, and male sex were associated with a higher rate of heart failure death. The direct comparisons between I-Preserve and the other 3 studies are limited in part by differences in enrollment criteria, patient demographics, and the event adjudication process. For example, DIG and CHARM enrolled patients of all ejection fraction values; DIG-Preserved analyzed patients with an ejection fraction Ͼ45%; and CHARM-Preserved Abbreviations as in Table 1 , plus CV indicates cardiovascular; SD, sudden death; and HF, heart failure. *Cause of heart failure was designated by the investigator. The 5-year all-cause mortality was Ϸ25%. There were no significant differences between placebo-and irbesartan-treated patients.
analyzed patients with an ejection fraction Ͼ40%. In DIGPreserved, events were not adjudicated by an end-point committee but rather were categorized by the local investigators. In I-preserve, patients were older, more often female, and less likely to have ischemic heart disease compared with CHARM-Preserved participants. In addition, some mode of death categories, eg, unknown and other vascular, were not reported in the other 3 studies. This may have changed the percentages reported in other categories. For example, in some RCTs in HFPEF and HFREF, patients adjudicated "as unknown" were placed in the cardiovascular mortality category as "other cardiovascular" mortality. All of these factors may have contributed to the differences in the numbers presented for each of these 4 studies.
Comparison With HFREF RCTs
To compare the results of the present study examining patients with HFPEF with results of previous studies examining patients with HFREF, the results of 20 previous HFREF studies were summarized and are presented in Table 6 . Fourteen studies examining the results of pharmacological studies 13-28 and 6 studies 29 -39 examining the results of device studies were averaged. This summary suggests that there are differences in the distribution of the mode of death categories between patients with HFREF and those with HFPEF. Noncardiovascular mortality was lower in HFREF than in HFPEF patients (15% versus 30%). Data from the present study suggest that 1 factor that may increase noncardiovascular mortality is related to age. In the present study, age Ն75 years was associated with a higher noncardiovascular mortality rate. The average age in studies of patients with HFREF is substantially lower than in studies of patients with HFPEF. The fact that noncardiovascular mortality is higher in HFPEF than HFREF also highlights one of the difficulties in the development and testing of new therapeutic strategies in patients with HFPEF. In fact, the ability to distinguish any potential therapeutic effect of irbesartan on cardiovascular mortality would be reduced when the effect on total mortality is examined.
When modes of death were analyzed as a percentage of all mortal events, sudden death and heart failure death were higher in HFREF than HFPEF patients. For example, in HFREF patients, the mode of death was sudden death in 40% of the total mortal events compared with 27% in HFPEF patients. In HFREF patients, the mode of death was heart failure death in 35% of the total mortal events compared with 15% in HFPEF patients. However, if mode of death is analyzed as a percentage of cardiovascular deaths, comparisons between HFPEF and HFREF show similar results. For example, in HFREF patients, the mode of death was sudden death in 48% of the cardiovascular deaths compared with 43% in HFPEF patients. In HFREF patients, the mode of death was heart failure death in 41% of the cardiovascular deaths compared with 24% in HFPEF patients.
Regardless of the method used to analyze these data, sudden death and heart failure death were the most common cardiovascular deaths in both the HFREF and HFPEF groups. These data suggest that we should pursue management strategies that could effectively reduce the incidence of sudden death and heart failure death in patients with HFPEF.
Insights Into the Pathophysiology of HFPEF
Defining the mode of death in the I-Preserve study provided important insights into the pathophysiology underlying the Sudden death, n (% of TM) 231 (26) 118 (27) 113 (25) With preceding CV symptoms, n (% of SD)
39 (17) 22 (19) 17 (15) Without preceding CV symptoms, n (% of SD)
85 (37) 44 (37) 41 (37) Unknown, n (% of SD) 106 (46) 52 (44) 54 (48) Heart failure, n (% of TM) 125 (14) 55 (13) 70 (16) Low output, n (% of HF) 1 (1) 0 (0) 1 (1) Congestion, n (% of HF) 30 (25) 15 (28) 15 (22) Low output and congestion, n (% of HF)
73 (60) 33 (61) 40 (59) Unknown, n (% of HF) 18 (15) 6 (11) 12 (18) MI, n (% of TM) 45 (5) 23 (5) 22 (5) Stroke, n (% of TM) 76 (9) 40 (9) 36 (8) Cardiovascular procedure, n (% of TM)
13 (1) 2 (0) 11 (2) Other cardiac death, n (% of TM) 10 (1) 6 (1) 4 (1) Other vascular death, n (% of TM) 32 (4) 21 (5) 11 (2) Noncardiovascular, n (% of TM) 268 (30) 134 (31) 134 (30) Renal, n (% of non-CV) 9 (3) 3 (2) 6 (5) Respiratory, n (% of non-CV) 19 (7) 11 (8) 8 (6) Cancer, n (% of non-CV) 104 (39) 52 (39) 52 (39) Trauma, n (% of non-CV) 6 (2) 2 (2) 4 (3)
Infection/sepsis, n (% of non-CV) 72 (27) 39 (30) 33 (25) Suicide, n (% of non-CV)
Other, n (% of non-CV) 51 (19) 24 (18) 27 (20) Unknown, n (% of TM) 81 (9) 37 (8) 44 (10) CV indicates cardiovascular mortality; TM, total mortality; SD, sudden death mortality; HF, heart failure mortality; and non-CV, noncardiovascular mortality.
presence of heart failure in patients with HFPEF. Despite the advanced age and the presence of comorbid states in patients with HFPEF, the mode of death was cardiovascular in 60% of the patients. In addition, the most common cardiovascular deaths in patients with HFPEF were heart failure death and sudden death. How do patients with HFPEF die of progressive heart failure or sudden death, and why is the rate lower than that observed in HFREF trials? A number of factors may affect the distribution of the mode of death categories in patients with heart failure. These factors include the extent of structural and functional abnormalities present such as the extent of systolic versus diastolic dysfunction and concentric versus eccentric remodeling. [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] Patients with HFREF have dominant abnormalities in systolic function, left ventricular dilation, and eccentric remodeling. In contrast, patients with HFPEF have dominant abnormalities in diastolic function, normal left ventricular size, and concentric remodeling. These structural and functional abnormalities may account for some of the differences in the distribution of the mode of death categories discussed below.
Heart failure deaths may be related to low output, congestion, or some combination of both. Cardiac output may decline as a result of a decline in ejection fraction; this effect, however, is buffered by progressive left ventricular dilation and eccentric remodeling, which may allow a normal stroke volume even in the presence of a low ejection fraction. In HFREF patients with an end-diastolic dimension of 7.0 to 7.5 cm (end-diastolic volume, Ϸ165 mL/m 2 ), an ejection fraction of 10% to 15% would produce a depressed stroke volume of Ϸ20 mL/m 2 and a cardiac index of only 1.4 L ⅐ m Ϫ2 ⅐ min Ϫ1 . The presence of reduced contractile function in patients with HFREF constrains the potential to increase stroke volume Figure 2 . A, Cumulative incidence of cardiovascular mortality rate in I-Preserve patients treated with placebo vs irbesartan. The 5-year cardiovascular mortality was Ϸ15%. There were no significant differences between placebo-and irbesartan-treated patients. B, Cumulative incidence of noncardiovascular mortality rate in I-Preserve patients treated with placebo vs irbesartan. The 5-year noncardiovascular mortality was Ϸ9%. There were no significant differences between placebo-and irbesartan-treated patients. Figure 3 . A, Cumulative incidence of or sudden death mortality rate in I-Preserve patients treated with placebo vs irbesartan. The 5-year sudden death mortality was Ϸ7%. There were no significant differences between placebo-and irbesartan-treated patients. B, Cumulative incidence of heart failure mortality rate in I-Preserve patients treated with placebo vs irbesartan. The 5-year heart failure mortality was Ϸ4%. There were no significant differences between placebo-and irbesartan-treated patients.
despite a large left ventricular end-diastolic volume. However, a normal ejection fraction does not necessarily indicate a normal stroke volume or cardiac output. Indeed, a low stroke volume should be expected in some patients with HFPEF (ie, those with small hearts and a low end-diastolic volume). For example, an end-diastolic dimension Ͻ4.5 cm may be present in as many as 20% of patients with HFPEF. 43, 44, 46, 48 A dimension of 4.0 to 4.5 cm (by echocardiography) corresponds to a volume of Ϸ80 mL or a body surface area of 40 mL/m 2 , and if the ejection fraction is 50% to 55%, the stroke volume could be as low as 20 mL/m 2 . At a heart rate of 70 to 100 bpm, the cardiac index might be only 1.4 L ⅐ m Ϫ2 ⅐ min Ϫ1 . Thus, some patients with HFPEF can exhibit a low cardiac output that is comparable to that seen in HFREF patients.
One consequence of decreased cardiac output is activation of neurohormonal mechanisms that lead to vasoconstriction, salt and water retention, and increased diastolic filling pressures. 55 Regardless of the ejection fraction, heart failure patients who develop acute decompensated heart failure have significant, progressive increases in left ventricular filling pressures. 49 Although left ventricular filling pressures were not measured in I-Preserve, heart failure death was adjudicated as a congestive state in most patients. Therefore, terminal patients with heart failure, regardless of whether they have HFREF or HFPEF, exhibit high left ventricular diastolic pressures, and some have a low cardiac output. Such heart failure can lead to circulatory failure and death.
Sudden death as an adjudicated mode of death may result from a variety of reasons, including ventricular arrhythmias Abbreviations as in Table 2 . *Rate per 1000 patient-years (No. of events).
(both tachycardias and bradycardias), heart block, and other causes of sudden hemodynamic collapse. Although the adjudication process cannot define the specific cause of sudden death, it is commonly presumed that many are related to arrhythmias. This is supported by the reduction in sudden death in HFREF trials using devices with a defibrillator function. The underlying clinical, structural, and functional factors that predispose to the development of arrhythmias may be similar in patients with HFREF and HFPEF; however, their frequency and severity may differ. For example, epicardial coronary artery disease causing ischemic heart disease is more common in patients with HFREF. In contrast, subendocardial ischemia related to increased left ventricular diastolic pressures in a left ventricle with concentric remodeling is more common in patients with HFPEF. Both forms of ischemia may lead to ventricular arrhythmias; however, coronary artery disease is likely to result in more frequent ischemia and to place larger areas of the myocardium at risk. Arrhythmias may also be related to myocardial fibrosis. Both patients with HFREF and those with HFPEF may have increased fibrosis; however, the pattern and extent of this fibrosis differ between the 2 groups. HFREF is associated with regional and patchy fibrosis, which more commonly leads to arrhythmias than the diffuse increase in extracellular matrix fibrillar collagen seen in patients with HFPEF. In addition, the myocardial fiber stretch that accompanies eccentric remodeling also contributes to a higher rate of arrhythmias in HFREF patients.
Therefore, both patients with HFREF and those with HFPEF have underlying pathophysiological conditions that make them vulnerable to the mechanisms that cause sudden death. Sudden death is not limited to patients with a low left ventricular ejection fraction. Indeed, the most common mode of cardiovascular death in HFPEF patients is sudden death.
Noncardiovascular death may be determined primarily by the patient's age and the number and nature of comorbidities present. The types of comorbidities present in patients with HFPEF are similar to those in patients with HFREF, and most occur at similar frequencies in HFPEF and HFREF patients.
However, hypertension is more common in patients with HFPEF. 56 -62 The number of comorbidities present is, to a large extent, dependent on age, with Ͼ55% of heart failure patients Ͼ65 years of age having Ն4 comorbidities. 59 In addition, the rate of noncardiovascular mortality in heart failure patients is directly proportional to the number and extent of comorbidities present. Thus, the number and extent of these comorbidities are greater in patients with HFPEF than in patients with HFREF in part because patients with HFPEF are older. 8 -39 The average age of patients in I-Preserve was 72 years compared with 62 years in previous HFREF trials. Therefore, these factors may have increased the extent of noncardiovascular deaths in patients with HFPEF.
The number of comorbidities may also contribute to the differences between mode of death distribution in RCTs and that seen in community-based epidemiological studies. For example, in the Olmsted County (Minneapolis), Minnesota, study of patients with heart failure, noncardiovascular mortality accounted for 49% of the total mortality. 58 This community study did not exclude any patients because of age or any comorbid conditions. As a result, the number and extent of comorbidities were greater than in RCTs. Additionally, other explanations for the differences between mode of death distribution in community and RCTs include differences in the heterogeneity and mortality risk of the populations studied, the use of end-point committees to adjudicate mode of death using prospectively defined mode of death definitions, and whether the study examines hospitalized or nonhospitalized patients.
Limitations: Methods of Assigning Mortal Event Classifications
At least 3 approaches can be used to assign mortal event classifications: mode of death, cause of death, and terminal event. Under most circumstances, each method would yield a different mortal event classification. For example, a patient collapses suddenly in the mall; a bystander places an automatic external defibrillator that shows ventricular fibrillation; emergency medical service personnel confirm the arrhythmia and complete an unsuccessful resuscitation attempt. A subsequent autopsy demonstrates a fresh MI. The mode of death is sudden death; the cause of death is an MI; the terminal event is ventricular fibrillation. Under other circumstances, there may be significant overlap between mortal event classification methods. For example, a patient has 5 successive hospitalizations for acute decompensated heart failure. The patient remains symptomatic with NYHA class IV symptoms and signs of heart failure between hospitalizations. The patient comes to the emergency room with another episode of acute decompensated heart failure, and the echocardiogram in the emergency room reveals an ejection fraction Ͼ55%. The patient then develops progressive hypoxia, is intubated, develops hypotension followed by ventricular fibrillation, and cannot be resuscitated. The mode of death and cause of death are heart failure, but the terminal event is ventricular fibrillation. Unfortunately, the level of detailed information and the autopsy available in the 2 examples above are not available in most RCTs and limit the Clinical End Point Committee's ability to adjudicate mortal events using all 3 mortal event classification methods. Therefore, for the purposes of the I-Preserve trial, the mode of death was used to assign mortal event classification. However, when sufficient information was available to enable the Clinical End Point Committee to "drill down" beyond the mode of death to a specific cause of death, this cause was adjudicated as the mortal event classification. The terminal event was not used to assign mortal event classification. It is possible that some of the differences between the present and previous studies may be based on the differences in the adjudication methods used.
Conclusions
The data presented in this study support the following conclusions. First, 60% of the deaths in patients with HFPEF were cardiovascular, with sudden death and heart failure being the most common. Second, the distribution of the mode of death categories in patients with HFPEF appeared different from that reported in patients with HFREF, with HFPEF patients having more noncardiovascular, fewer sudden, and fewer heart failure deaths than HFREF patients. Third, treatment with irbesartan did not affect overall mortality or the distribution of mode-specific mortality rates. The results of the I-Preserve trial provide significant insight into the pathophysiology of HFPEF and may provide a basis for the development of more effective management strategies.
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CLINICAL PERSPECTIVE
Defining the mode of death in patients with heart failure and a preserved ejection fraction (HFPEF) may help to improve our understanding of the underlying pathophysiology in these patients with heart failure and provide insights into appropriate targets for the development of new therapies. Despite advanced age and the presence of comorbid states in patients with HFPEF, the mode of death was cardiovascular in 60% of the patients. In addition, the most common modes of cardiovascular death in patients with HFPEF were heart failure death and sudden death. These facts have implications both for the development of novel management strategies and for the design of future studies to test these strategies in patients with HFPEF. Management strategies that reduce causes of sudden death (such as reduction of arrhythmias) and prevent progression of heart failure (such as improvement in diastolic function and reduction of diastolic pressures) may be able to decrease cardiovascular death rates in patients with HFPEF. Therefore, new management strategies for patients with HFPEF should focus on treatments that can reduce arrhythmias and improve diastolic function. However, management strategies that target cardiovascular causes of mortality are not likely to affect the 30% of mortalities caused by noncardiovascular modes of death. Therefore, treatment of patients with HFPEF should also target the noncardiovascular comorbid states that are commonly present in these patients.
